The PALB2 Gene Pancreatic Cancer Type 3 Susceptibility Genetic Test is a specialized medical examination offered by DNA Labs UAE, designed to assess an individual's genetic predisposition to developing Type 3 Pancreatic Cancer. This test specifically analyzes the PALB2 gene, which plays a crucial role in DNA repair processes. Mutations in the PALB2 gene have been associated with an increased risk of developing pancreatic cancer, among other types of cancers. By identifying variations within this gene, the test can provide valuable insights into an individual's risk factors, potentially guiding preventive measures and personalized surveillance strategies.
The process involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of specific genetic mutations in the PALB2 gene. This test is particularly recommended for individuals with a family history of pancreatic cancer or known genetic predispositions, as it can offer early warnings and facilitate proactive health management.
The cost of the PALB2 Gene Pancreatic Cancer Type 3 Susceptibility Genetic Test at DNA Labs UAE is set at 4400 AED. Given the complexity of the analysis and the potential life-saving insights it can provide, many consider it a valuable investment in their health and well-being.
The CDKN2A Gene Pancreatic Cancer-Melanoma Syndrome Familial Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to detect mutations in the CDKN2A gene, which are strongly associated with an increased risk of developing familial atypical multiple mole melanoma (FAMMM) syndrome. This syndrome significantly elevates the risk for both melanoma, a serious form of skin cancer, and pancreatic cancer among affected individuals and their families. By analyzing an individual's genetic material, the test aims to identify specific mutations in the CDKN2A gene that are linked to these cancers, providing crucial information for early detection, prevention, and management strategies for at-risk families. The test is priced at 4400 AED and is a vital tool in the realm of genetic counseling and personalized medicine, offering a proactive approach to managing and mitigating the risks associated with these hereditary cancer syndromes.
The EZH2 gene plays a significant role in the development and progression of various forms of cancer, including leukemia, both lymphoblastic and myeloid types. The EZH2-related genetic test is a specialized diagnostic tool designed to detect mutations in the EZH2 gene, which can be indicative of a predisposition to these types of cancers or can influence the course of the disease and treatment options. This test is particularly important for patients who are at risk of developing leukemia or those who have been diagnosed and require a detailed genetic profile to guide their treatment plan.
Conducted at DNA Labs UAE, a leading facility in genetic testing and diagnostics, the EZH2-related genetic test is performed with precision and accuracy, utilizing the latest technology in genetic sequencing. The cost of the test is 4400 AED, an investment in health that provides crucial information for the management and treatment of leukemia. By identifying specific mutations in the EZH2 gene, healthcare providers can tailor treatment approaches to the individual's genetic profile, potentially improving outcomes and offering targeted therapies.
This test is recommended for individuals with a family history of leukemia, those diagnosed with leukemia seeking more detailed genetic information, or patients not responding to conventional treatments. The results from the EZH2-related genetic test can significantly impact the therapeutic strategy, offering hope for more effective and personalized cancer care.
The CEBPA gene plays a critical role in the development and function of various types of cells, including those in the blood-forming system. Mutations in this gene can lead to acute myeloid leukemia (AML), a rapid-growing cancer of the blood and bone marrow. Specifically, germline mutations in the CEBPA gene are associated with a familial predisposition to AML, making individuals with such mutations at a higher risk of developing this form of leukemia.
To identify the presence of germline mutations in the CEBPA gene, a specialized genetic test is conducted. This test is crucial for individuals with a family history of AML or those who have been diagnosed with the disease, as it helps in determining the genetic underpinnings of the condition. Understanding whether the leukemia is caused by a CEBPA germline mutation can significantly impact treatment decisions and risk assessments for family members.
In the United Arab Emirates, DNA Labs UAE offers this important genetic test. The cost of the test is set at 4400 AED. The test involves analyzing the patient's DNA, extracted from a blood sample, to look for mutations in the CEBPA gene. Results from this test can provide valuable insights into the patient's condition, enabling personalized treatment plans and informing family members about their potential risk, guiding them in taking preventive measures or considering their own genetic testing.
The TP53 Gene Li-Fraumeni Syndrome Type 1 Genetic Test is a specialized medical examination offered by DNA Labs UAE, designed to detect mutations in the TP53 gene. This gene plays a critical role in controlling cell growth and division. Mutations in TP53 can lead to Li-Fraumeni syndrome, a rare, inherited disorder that significantly increases the risk of developing various types of cancer, including breast cancer, brain tumors, leukemia, and sarcomas, often at a young age.
The test, priced at 4400 AED, involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the lab to identify any genetic alterations in the TP53 gene. Early detection through this genetic test is crucial for individuals with a family history of Li-Fraumeni syndrome or early-onset cancers, as it allows for proactive surveillance, early cancer detection, and tailored preventive measures, potentially improving survival rates and quality of life for affected individuals and their families.
The CHEK2 Gene Li-Fraumeni Syndrome Type 2 Genetic Test is a crucial diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the CHEK2 gene, which are associated with a higher risk of developing Li-Fraumeni Syndrome Type 2. This syndrome is a rare, hereditary disorder that significantly increases an individual's susceptibility to a wide range of cancers, including breast cancer, brain tumors, and sarcomas, among others. Early detection through this genetic test allows for proactive monitoring and management of cancer risks, enhancing the chances of early intervention and treatment. The test is priced at 4400 AED and is conducted with precision and confidentiality, providing individuals and families with critical information for health planning and management.
The SUFU Gene Medulloblastoma Desmoplastic Familial Genetic Test is a specialized diagnostic procedure offered at DNA Labs UAE, designed to identify mutations in the SUFU gene, which are linked to an increased risk of developing desmoplastic medulloblastoma, a rare form of brain tumor. This test is particularly important for individuals with a family history of this condition, as it can provide vital information regarding their genetic predisposition to developing the disease. Early detection through genetic testing allows for timely interventions and personalized treatment plans, significantly improving patient outcomes. The test is priced at 4400 AED and is conducted using advanced genomic technologies to ensure high accuracy and reliability of results.
The CDKN2A Gene Melanoma and Neural System Tumor Syndrome Familial Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE. This test is designed to identify mutations in the CDKN2A gene, which are strongly associated with an increased risk of developing melanoma, a type of skin cancer, as well as tumors within the neural system. The CDKN2A gene plays a crucial role in regulating cell division and preventing cells from growing uncontrollably, which can lead to tumor formation. Mutations in this gene can disrupt its function, thereby increasing the risk of cancer.
Familial genetic testing for the CDKN2A gene is particularly important for individuals with a family history of melanoma or neural system tumors, as it can help in early detection and management of these conditions. Knowing one's genetic status regarding the CDKN2A gene can enable healthcare providers to tailor a more precise surveillance and prevention strategy, potentially improving outcomes and quality of life for those at risk.
The test is performed at DNA Labs UAE, a facility known for its advanced genetic testing services. The cost of the CDKN2A Gene Melanoma and Neural System Tumor Syndrome Familial Genetic Test is 4400 AED. This price reflects the comprehensive nature of the test, including the extraction of DNA, the sophisticated analysis to identify mutations in the CDKN2A gene, and the provision of a detailed report that can guide further medical action. Individuals considering this test are encouraged to consult with their healthcare provider to understand its implications fully and how it fits into their overall health management strategy.
The MC1R Gene Melanoma Cutaneous Malignant Genetic Test is a specialized diagnostic tool designed to identify mutations in the MC1R gene, which are associated with an increased risk of developing cutaneous malignant melanoma, a serious type of skin cancer. This test is particularly crucial for individuals with a family history of melanoma or those who have a personal history of skin cancer, as it can provide valuable insights into their genetic predisposition to the disease. By analyzing the MC1R gene, healthcare professionals can offer personalized advice on prevention strategies and closely monitor those at elevated risk, potentially leading to early detection and improved treatment outcomes.
The test is available at DNA Labs UAE, a leading provider of genetic testing services in the United Arab Emirates. The cost of the MC1R Gene Melanoma Cutaneous Malignant Genetic Test is 4400 AED. DNA Labs UAE employs cutting-edge technology and adheres to strict quality standards to ensure accurate and reliable test results. By opting for this test, individuals can take a proactive step towards understanding their genetic risk for melanoma and make informed decisions about their health and well-being.
The "MITF Gene Melanoma Cutaneous Malignant Genetic Test" is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the MITF gene that are associated with an increased risk of developing cutaneous malignant melanoma. The MITF gene plays a crucial role in the development and function of melanocytes, cells responsible for pigment production in the skin. Mutations in this gene can lead to abnormal cell growth and the formation of melanoma, a serious and potentially deadly form of skin cancer.
This test is particularly recommended for individuals with a family history of melanoma or those who have been identified as having a higher risk of developing this type of cancer. Early detection of MITF gene mutations allows for timely intervention and personalized management strategies to mitigate the risk of melanoma development.
The cost of the test is 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify the genetic variations associated with melanoma risk. Conducted at DNA Labs UAE, a facility known for its state-of-the-art genetic testing services, clients are assured of receiving reliable and comprehensive results. This test represents a critical step forward in the personalized medicine approach to cancer prevention and management, offering individuals a proactive means of assessing their melanoma risk.
